Core Insights - The "Maker China" Shenzhen Innovation and Entrepreneurship Competition concluded successfully, with KFH Biotech winning the first prize in the enterprise category for its project focused on AI-assisted drug development for neurological diseases [1][3]. Company Overview - KFH Biotech specializes in utilizing artificial intelligence technology to accelerate new drug development, particularly targeting difficult-to-treat neurological diseases such as ALS, chemotherapy-induced neuropathy, and diabetic neuropathy [3]. - The company has established a mature AI drug development platform that enhances the efficiency and success rate of new drug research by enabling molecular structure design, active ingredient screening, and safety and efficacy predictions [3][4]. Product Development - KFH Biotech has advanced multiple new drugs into critical research stages, including an oral medication for autoimmune diseases that received clinical trial approval from both Chinese and U.S. regulatory authorities in 2024 and successfully completed Phase I trials [4]. - The company is also expanding its research into cancer and autoimmune diseases, effectively balancing development risks and accelerating the market entry of new drugs to benefit patients [4]. Support and Environment - The Longcheng Street has actively supported local enterprises by guiding them through key processes such as technology-based SME evaluations and high-tech enterprise applications, as well as facilitating talent policy connections [3]. - The street continues to optimize the park's supporting facilities and innovation environment, providing robust support for enterprises to focus on research and accelerate growth [3][4].